Evidence map›Paper›PMID 25483299›Full record

ReviewSmall GTPases2014

Vav family exchange factors: an integrated regulatory and functional view.

Xosé R Bustelo

Open access · bronzeAbstract readReview
In one paragraph

Review in Small GTPases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 146 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Anti-Tumour Immunity Relies on Targeting Tissue Homeostasis Through Monocyte-Driven Responses Rather Than Direct Tumour Cytotoxicity.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Article
  13. Article
  14. Article
  15. RAC1 signaling in prostate cancer: VAV GEFs take center stage.Frontiers in cell and developmental biology · 2025
    Article
  16. Article
  17. Prognostic Significance ofBiomedicines · 2024
    Article
  18. Article
  19. Article
  20. Review

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Xosé R Busteloa Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer ; Consejo Superior de Investigaciones Científicas (CSIC) and University of Salamanca ; Campus Unamuno; Salamanca , Spain.
Universidad de Salamanca · ES

Funding

VAV FAMILY PROTEINS IN CELL SIGNALING AND CANCERR01CA073735 · NCI · UNIVERSITY OF SALAMANCA · PI BUSTELO, XOSE R · 1997 to 2009
$1.8M
NCI NIH HHS R01CA7373509Worldwide Cancer Research 14-1248
6 · The paper itself

Abstract

The Vav family is a group of tyrosine phosphorylation-regulated signal transduction molecules hierarchically located downstream of protein tyrosine kinases. The main function of these proteins is to work as guanosine nucleotide exchange factors (GEFs) for members of the Rho GTPase family. In addition, they can exhibit a variety of catalysis-independent roles in specific signaling contexts. Vav proteins play essential signaling roles for both the development and/or effector functions of a large variety of cell lineages, including those belonging to the immune, nervous, and cardiovascular systems. They also contribute to pathological states such as cancer, immune-related dysfunctions, and atherosclerosis. Here, I will provide an integrated view about the evolution, regulation, and effector properties of these signaling molecules. In addition, I will discuss the pros and cons for their potential consideration as therapeutic targets.

Indexed as

Signal TransductionAmino Acid SequenceAnimalsHumansMolecular Sequence DataProto-Oncogene Proteins c-vavrho GTP-Binding ProteinsProto-Oncogene Proteins c-vavrho GTP-Binding ProteinsAc, acidicAhr, aryl hydrocarbon receptorcancercardiovascular biologycGMP, cyclic guanosine monophosphateCH, calponin homologyCSH3, most C-terminal SH3 domain of Vav proteinsDAG, diacylglycerolDbl-homologyDH, Dbl-homology domaindiseaseGDP/GTP exchange factorsGEF, guanosine nucleotide exchange factorHIV, human immunodeficiency virusimmunologyIP3, inositoltriphosphatenervous systemNFAT, nuclear factor of activated T-cellsNSH3, most N-terminal SH3 domain of Vav proteinsPhox, phagocyte oxidasePH, plekstrin-homology domainPI3K, phosphatidylinositol-3 kinasePIP3, phosphatidylinositol (3,4,5)-triphosphatePKC, protein kinase CPKD, protein kinase DPLC-g, phospholipase C-gPRR, proline-rich regionPTK, protein tyrosine kinaseRho GTPasesSH2, Src homology 2SH3, Src homology 3signalingSNP, single nucleotide polymorphismTCR, T-cell receptortherapiesVavZF, zinc finger region

Identifiers

PMID25483299
PMCPMC4601183
OpenAlexW2334793775

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.